Literature DB >> 8376493

Limited extent of stereochemical conversion of chiral non-steroidal anti-inflammatory drugs induced by derivatization methods employing ethyl chloroformate.

M R Wright1, F Jamali.   

Abstract

A potential problem with chiral derivatization is the possibility of stereochemical conversion during the derivatization reaction. This possibility has been examined using the non-steroidal anti-inflammatory drugs ibuprofen, ketoprofen, etodolac and flurbiprofen. To avoid possible interference from stereochemical impurities, male Sprague-Dawley rats were dosed intraperitoneally with the S enantiomer (100 mg/kg) of each drug and the R enantiomer of etodolac. Blood samples were taken 4 h afterwards. The plasma samples were analyzed using published stereospecific methods involving chiral derivatization with ethyl chloroformate followed by either R-(+)-alpha-phenylethylamine or L-leucinamide. For all the drugs examined, the percentage of formation of the antipode was between 1.0 and 5.8%. In vitro studies of the R and S enantiomers demonstrate that the apparent extent of conversion is inversely related to the concentration of ethyl chloroformate present during the derivatization reaction for ibuprofen, ketoprofen and flurbiprofen but not for etodolac. However, both the R and S enantiomers appear to be inverted to the same extent in the presence of ethyl chloroformate. These results suggest that the degree of stereochemical conversion induced by these assay procedures is small and would not contribute significantly to analytical error in the absence of a large difference in concentrations of the enantiomers.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8376493     DOI: 10.1016/0378-4347(93)80471-f

Source DB:  PubMed          Journal:  J Chromatogr


  5 in total

Review 1.  Clinical pharmacokinetics of dexketoprofen.

Authors:  M J Barbanoj; R M Antonijoan; I Gich
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats.

Authors:  M Vakily; B Corrigan; F Jamali
Journal:  Pharm Res       Date:  1995-11       Impact factor: 4.200

Review 3.  Etodolac clinical pharmacokinetics.

Authors:  D R Brocks; F Jamali
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

Review 4.  Enantiospecific analysis: applications in bioanalysis and metabolism.

Authors:  A J Hutt; M R Hadley; S C Tan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Jul-Sep       Impact factor: 2.441

5.  Spectrophotometric determination of etodolac in pure form and pharmaceutical formulations.

Authors:  Ayman A Gouda; Wafaa S Hassan
Journal:  Chem Cent J       Date:  2008-04-14       Impact factor: 4.215

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.